Ardelyx Earnings Call: Ibsrela Surge Fuels Bold Targets

Ardelyx Inc ((ARDX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Ardelyx’s latest earnings call painted a broadly upbeat picture, with management leaning into strong demand trends while acknowledging rising costs and market risks. Executives highlighted powerful Ibsrela momentum, solid overall revenue growth, and advancing clinical programs, yet cautioned that elevated operating expenses and competitive threats could delay a clear path to sustained profitability.

Robust Q1 Revenue Expansion Fueled by Ibsrela

Ardelyx reported total product revenue of $93.4 million for the first quarter of 2026, a 38% increase from $67.8 million a year earlier. Management attributed the bulk of that growth to higher Ibsrela prescriptions, underscoring that demand strength more than offset seasonal and weather-related headwinds.

Ibsrela Momentum Underpins Aggressive Growth Ambitions

Ibsrela delivered $70.1 million in Q1 revenue, up 58% year over year as adoption in chronic idiopathic constipation continued to build. The company reaffirmed 2026 Ibsrela guidance of $410 million to $430 million and reiterated its longer-term goal of at least $1 billion in annual Ibsrela sales by 2029, implying a roughly 38% compound growth trajectory.

Exposa Shows Underlying Growth Despite Flat GAAP Line

Exposa generated $23.3 million in Q1 revenue, appearing essentially flat versus last year due to a favorable $3.8 million return reserve recorded in the prior period. Adjusting for that accounting effect, management said paid prescriptions rose about 19% and reiterated a long-term Exposa sales target of $750 million and 2026 guidance of $110 million to $120 million.

Pipeline Advances with EXCEL Phase 3 and Pediatric Studies

The company launched the EXCEL Phase 3 trial of Ibsrela in chronic idiopathic constipation, noting that all pre-identified sites were activated in under four months and enrollment should finish by year-end. Topline data are expected in 2027, while ongoing pediatric studies and a newly listed 2099 patent could extend market exclusivity and broaden the label over time.

Next-Generation NHE3 Inhibitor Broadens Future Optionality

Ardelyx is advancing its next-generation NHE3 inhibitor, referred to as 531, through IND-enabling work. Management framed the asset as a potential platform for expansion into additional therapeutic areas, positioning the company for a second wave of pipeline-driven growth beyond the current Ibsrela and Exposa franchises.

Commercial Initiatives Boost Fulfillment and Refills

The Ibsrela Pharmacy Network and expanded field reimbursement support are helping patients navigate access and coverage hurdles, according to management. The specialty pharmacy channel now represents roughly 30% of prescriptions and is producing higher fill rates and approximately one extra refill per patient annually, enhancing revenue pull-through.

Improving Loss Profile and Strengthened Balance Sheet

Ardelyx narrowed its net loss to $37.6 million, or $0.15 per share, from $41.1 million, or $0.17 per share, in the prior-year quarter. The company ended Q1 with $238.1 million in cash, cash equivalents and short-term investments, while a refinanced $300 million debt facility extended maturities, lowered borrowing costs and preserved $100 million of undrawn capacity.

Rising Operating Expenses Pressure Near-Term Profitability

Operating costs climbed sharply as Ardelyx invested in commercialization and late-stage trials, with SG&A rising about 23% to $102.3 million and R&D up roughly 36% to $20.2 million. Management guided to around $520 million in total operating expenses for 2026, implying about 25% growth and leaving little margin for error as revenue ramps toward the lower end of its forecast.

Exposa Reporting Complexity Masks Dialysis Market Volatility

Management cautioned that Exposa’s as-reported revenue understates underlying prescription growth because of prior-year reserve adjustments that benefited 2025 results. They also flagged ongoing volatility in payer behavior and the dialysis channel, which can distort GAAP trends even as the company works to deepen adoption and manage returns more tightly.

Seasonality and Storms Add Noise to Quarterly Trends

Executives pointed to typical first-quarter seasonality as a headwind for both demand and reported revenue, especially given insurance resets. Two severe winter storms further disrupted distribution and patient access in some regions, creating temporary noise in prescription data that management expects to normalize over subsequent quarters.

Gross-to-Net Dynamics Weigh on Early-Year Realization

Ardelyx reported a blended gross-to-net rate of about 36.4% in the first quarter, higher than what it expects for the full year. The company attributed the spike to first-quarter deductible and copay patterns and suggested that the blended gross-to-net should settle in the low-30% range for 2026 as seasonal cost-sharing dynamics ease later in the year.

Ongoing Net Losses Keep Cash-Flow Turning Point in Focus

Despite improving losses, Ardelyx remains a loss-making company and acknowledged that operating expenses are roughly in line with the low end of its revenue outlook. Management emphasized that achieving sustainable cash-flow positivity will depend on flawless execution of its growth plan, especially for Ibsrela, amid continued investment in commercial and R&D initiatives.

Emerging Competitive Threat from GLP-1 Programs

The company highlighted potential competition from GLP-1 therapies under development for IBS-C, including programs at larger pharmaceutical players with data expected later this decade. While management remains confident in Ibsrela’s differentiated mechanism and current positioning, it acknowledged that successful GLP-1 entries could challenge the long-term durability of the Ibsrela franchise in certain patient subsets.

Guidance Reinforces Confidence in Multi-Year Growth Path

Ardelyx reaffirmed 2026 product revenue guidance of $520 million to $550 million, implying 38% to 46% year-over-year growth, with Ibsrela expected to deliver $410 million to $430 million and Exposa $110 million to $120 million. Management projected steady quarter-over-quarter demand increases, maintained its 2029 Ibsrela target of at least $1 billion, and reiterated that expenses will rise about 25% as it funds commercial and clinical expansion.

Ardelyx’s earnings call delivered a clear message: the company is leaning hard into growth, with Ibsrela and Exposa driving higher sales and a pipeline designed to extend the runway. Investors, however, will need to balance that momentum against rising operating costs, complex reimbursement dynamics and future GLP-1 competition as they assess the durability of the current growth story.